Can serum NGAL levels be used as an inflammation marker on hemodialysis patients with permanent catheter?

dc.contributor.authorYigit, Irem Pembegul
dc.contributor.authorCeliker, Huseyin
dc.contributor.authorDogukan, Ayhan
dc.contributor.authorIlhan, Necip
dc.contributor.authorGurel, Ali
dc.contributor.authorUlu, Ramazan
dc.contributor.authorAygen, Bilge
dc.date.accessioned2026-08-12T17:48:23Z
dc.date.issued2015
dc.departmentFırat Üniversitesi
dc.description.abstractBackground: Neutrophil gelatinase-associated lipocalin (NGAL) is a member of lipocalin family and released from many tissues and cells. We aimed to investigate the relationship among serum NGAL levels, the inflammation markers (IL-6, hs-CRP, TNF-alpha) and different vascular access types used in dialysis patients. Methods: The study population included 90 patients and 30 healthy age-matched controls. The patients were divided into three groups (I, II, III) and group IV included the controls. In group I and II, the patients were with central venous permanent catheter and arterio-venous fistula, respectively. Group III included 30 patients with chronic renal failure. Hemogram, biochemical assays, ferritin, IL-6, hs-CRP, TNF-alpha, and NGAL were evaluated in all groups. Results: Serum NGAL levels were markedly higher in group I than in group II (7645.80 +/- 924.61 vs. 4131.20 +/- 609.87 pg/mL; p < 0.05). Positive correlation was detected between NGAL levels and duration of catheter (r: 0.903, p: 0.000), hs-CRP (r: 0.796, p: 0.000), IL-6 (r: 0.687, p: 0.000), TNF-alpha (r: 0.568, p: 0.000) levels and ferritin (r: 0.318, p: 0.001), whereas NGAL levels were negatively correlated with serum albumin levels (r: -0.494, p: 0.000). In multiple regression analysis, duration of catheter hs-CRP and TNF-alpha were predictors of NGAL in hemodialysis patients. Conclusion: Inflammation was observed in hemodialysis patients and increases with catheter. Our findings show that a strong relationship among serum NGAL levels, duration of catheter, hs-CRP and TNF-alpha. NGAL may be used as a new inflammation marker in hemodialysis patients.
dc.description.sponsorshipFirat University Scientific Research Foundation
dc.description.sponsorshipThis study was supported by Firat University Scientific Research Foundation.
dc.identifier.doi10.3109/0886022X.2014.975133
dc.identifier.endpage82
dc.identifier.issn0886-022X
dc.identifier.issn1525-6049
dc.identifier.issue1
dc.identifier.orcid0000-0001-9997-0418
dc.identifier.pmid25347233
dc.identifier.scopus2-s2.0-84919458947
dc.identifier.scopusqualityQ2
dc.identifier.startpage77
dc.identifier.urihttps://doi.org/10.3109/0886022X.2014.975133
dc.identifier.urihttps://hdl.handle.net/11508/61410
dc.identifier.volume37
dc.identifier.wosWOS:000346633700013
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofRenal Failure
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectCentral venous permanent catheter
dc.subjecthemodialysis
dc.subjectinterleukin-6
dc.subjectneutrophil gelatinase-associated lipocalin
dc.subjecttumor necrosis factor-alpha
dc.titleCan serum NGAL levels be used as an inflammation marker on hemodialysis patients with permanent catheter?
dc.typeArticle

Dosyalar